Syndax Pharmaceuticals ends idiopathic pulmonary fibrosis program after phase 2 trial failure
Syndax Pharmaceuticals discontinued development of Niktimvo for idiopathic pulmonary fibrosis after a mid-stage trial failed to meet its primary endpoint. The company's shares fell 17% in extended trading following the announcement.
6 sourcesPharmaceutical Industry
00